BioMarin Rolls Up Sleeves To Prepare For Roctavian’s EU Debut
Positive CHMP Opinion Makes Approval Likely
The company plans to start in Germany with an outcomes-based payment model. But while a US FDA nod seems likely, analysts have been more cautious about calling US approval a done deal.
